Literature DB >> 9266447

Analyses of human gliomas by restriction landmark genomic scanning.

M Nakamura1, N Konishi, S Tsunoda, Y Hiasa, T Tsuzuki, H Aoki, K Kobitsu, H Nagai, T Sakaki.   

Abstract

The 16 primary gliomas were examined for changes in genomic DNA using a recently developed 2-dimensional gel electrophoresis method called restriction landmark genomic scanning (RLGS). This approach allows detection of DNA amplification, deletion, methylation and potentially other genetic rearrangements represented as decreases and increases in spot/fragment intensity on an autoradiogram. Approximately 2,000 landmark sites in tumor DNA were compared with those of DNA isolated from normal brain tissues. Seven spots showing intensified signal were consistently detected in at least 50% of tumors, implying activation of corresponding DNA sequences, and 8 additional spots having reduced signal were observed, again in more than 50% of all tumors, suggesting inactivation by the loss of 1 allele or homozygous deletion. Decreased signal may also infer relative CpG island methylation state. Of those spots consistently identified in tumors, 2 amplified and 4 reduced spots were found to be characteristic of low- and high-grade tumors, while the remaining 5 amplified and 4 reduced spots were associated with high-grade gliomas only, suggesting a link of specific mutations to degree of malignancy. A separate subset of glioblastomas evaluated, however, showed no alterations in these 'hot spots' which were detected in even low grade astrocytomas. The results demonstrate the genetic heterogeneity of glioblastoma and implicate the progression of neoplasia via differing genetic pathways.

Entities:  

Mesh:

Year:  1997        PMID: 9266447     DOI: 10.1023/a:1005712308061

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  A genomic scanning method for higher organisms using restriction sites as landmarks.

Authors:  I Hatada; Y Hayashizaki; S Hirotsune; H Komatsubara; T Mukai
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

2.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

3.  Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.

Authors:  T Tsuzuki; S Tsunoda; T Sakaki; N Konishi; Y Hiasa; M Nakamura
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

4.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

5.  Genomic aberrations in human hepatoblastomas detected by 2-dimensional gel analysis.

Authors:  H Nagai; H Tsumura; M Ponglikitmongkol; Y S Kim; K Matsubara
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  The retinoblastoma gene is involved in malignant progression of astrocytomas.

Authors:  J W Henson; B L Schnitker; K M Correa; A von Deimling; F Fassbender; H J Xu; W F Benedict; D W Yandell; D N Louis
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

7.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

Authors:  D Fults; D Brockmeyer; M W Tullous; C A Pedone; R M Cawthon
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

8.  Subsets of glioblastoma multiforme defined by molecular genetic analysis.

Authors:  A von Deimling; K von Ammon; D Schoenfeld; O D Wiestler; B R Seizinger; D N Louis
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

9.  Genetic variation detected by quantitative analysis of end-labeled genomic DNA fragments.

Authors:  J Asakawa; R Kuick; J V Neel; M Kodaira; C Satoh; S M Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

View more
  2 in total

Review 1.  Molecular epigenetics and genetics in neuro-oncology.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 2.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.